A5073509371- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- T-cell and B-cell Immunology
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Immune cells in cancer
- Cancer-related gene regulation
- Endoplasmic Reticulum Stress and Disease
- Biosimilars and Bioanalytical Methods
- Metabolomics and Mass Spectrometry Studies
- Cancer, Hypoxia, and Metabolism
- CNS Lymphoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Autophagy in Disease and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Glioma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Virus-based gene therapy research
University of Michigan
2016-2025
Michigan Medicine
2021-2024
U-M Rogel Cancer Center
2019-2024
Medical College of Wisconsin
2020
Michigan United
2017-2019
University of Pennsylvania
2011-2018
UPMC Hillman Cancer Center
2011
Cancer Research Institute
2011
National Institutes of Health
2008
Max Planck Institute for Metabolism Research
2008
Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated (ABC) and primary mediastinal (PMBL). To investigate whether these DLBCL arise by distinct pathogenetic mechanisms, we analyzed 203 biopsy samples high-resolution, genome-wide copy number analysis coupled with gene-expression profiling. Of 272 recurrent chromosomal aberrations that were associated alterations, 30...
The molecular basis for the inverse relationship between differentiation and tumorigenesis is unknown. function of runx2, a master regulator osteoblast belonging to runt family tumor suppressor genes, consistently disrupted in osteosarcoma cell lines. Ectopic expression runx2 induces p27KIP1, thereby inhibiting activity S-phase cyclin complexes leading dephosphorylation retinoblastoma protein (pRb) G1 cycle arrest. Runx2 physically interacts with hypophosphorylated form pRb, known...
Abstract T cell differentiation requires appropriate regulation of DNA methylation. In this article, we demonstrate that the methylcytosine dioxygenase ten-eleven translocation (TET)2 regulates CD8+ differentiation. a murine model acute viral infection, TET2 loss promotes early acquisition memory fate in cell-intrinsic manner without disrupting Ag-driven expansion or effector function. Upon secondary recall, TET2-deficient cells superior pathogen control. Genome-wide methylation analysis...
T cell proliferation and cytokine production are bioenergetically biosynthetically costly. The inability to meet these metabolic demands results in altered differentiation, accompanied by impaired effector function, attrition of the immune response. Interleukin-17–producing CD4 cells (T H 17s) mediators host defense, autoimmunity, antitumor immunity setting adoptive therapy. 17s long-lived that require mitochondrial oxidative phosphorylation (OXPHOS) for function vivo. Considering polarized...
Conventional and nonconventional T cell development occur in the thymus. Nonconventional thymocytes that bear characteristics typically associated with innate immune cells are termed innate-like lymphocytes (ILLs). Mice harboring a tyrosine to phenylalanine mutation adaptor protein Src homology 2 domain-containing leukocyte of 76 kDa at residue 145 (Y145F mice) develop an expanded population CD8(+)CD122(+)CD44(+) ILLs, typified by expression T-box transcription factor eomesodermin. Y145F...
Abstract The retinoblastoma protein, pRb, can activate the transcription factor RUNX2, an essential regulator of osteogenic differentiation, but mechanism this activation is unknown. Here we studied interaction pRb and RUNX2 with HES1, previously reported to augment activity. PRb act promote RUNX2/HES1 association concomitant promoter occupancy transcriptional in bone cells. Introduction: (also known as OSF2/CBFA1) a required for osteoblast differentiation formation. We have that associate...
Interleukin (IL)-4 is a cytokine classically associated with CD4+ T helper type 2 differentiation, but has been recently shown to also be required for the development of CD8+ innate-like lymphocytes. lymphocytes are non-conventional that exhibit characteristics typically memory cells, including expression T-box transcription factor Eomesodermin (Eomes). Here we investigate signaling pathways IL-4 induction Eomes and lymphocyte markers in murine CD8SP thymocytes peripheral cells. We...
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who untreated. Over the last several years, targeted or small-molecule therapies have shown efficacy relapsed/refractory setting since been explored frontline setting. Lenalidomide plus rituximab was phase 2 study 38 MCL were untreated ineligible to receive transplantation, which combination...
T cell development in the thymus produces multiple lineages of cells, including innate cells such as γδ TCR(+) invariant NKT mucosal-associated and H2-M3-specific cells. Although are generally a minor subset thymocytes, several strains mice harboring mutations signaling proteins or transcriptional regulators, conventional CD8(+) develop with characteristics memory Thus, Itk-deficient mice, mature CD4(-)CD8(+) (CD8 single-positive [SP]) thymocytes express high levels transcription factor...
CD8
7505 Background: MCL is a rare lymphoma without standard of care but several regimens have demonstrated clinical activity, the majority based on traditional chemotherapy. We hypothesized that adding venetoclax (V) to R2 would be safe and effective in pts irrespective age, morphology or stage. Here we present safety efficacy data from on-going phase 1b study + V with newly diagnosed MCL. Methods: This multi-center 1 (NCT03523975) enrolled aged ≥18 yrs untreated The primary objective was...
COVID-19 infection and vaccination may be associated with a wide variety of cutaneous immune manifestations. Here, we describe two patients who presented monoclonal T-cell infiltrates that showed cytologic immunophenotypic features concerning for lymphoma shortly following vaccination. In one case, the eruption completely resolved. The second patient initial resolution, but her disease recurred progressed breakthrough SARS-CoV-2 infection. These cases suggest stimulation exposure to...
Abstract: Mantle cell lymphoma (MCL) is an incurable intermediate-grade representing 5–6% of non-Hodgkin's lymphomas diagnosed in the United States. The introduction inhibitors Bruton's tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes patients with relapsed/refractory (R/R) disease. Since initial approval first-generation inhibitor, ibrutinib, several second-generation have been explored. Acalabrutinib, a BTK demonstrated impressive efficacy clinical...
Hydroa vacciniforme-like lymphoproliferative disorders (HVLPDs) arise from chronic active Epstein-Barr virus (EBV) infection of T cells and natural killer cells. The term HVLPD was introduced in the 2016 World Health Organization classification lymphoid neoplasms1 to reflect spectrum EBV-related cutaneous classic hydroa vacciniforme (HV) severe HV HV-like lymphoma (HVLL). Although has no geographic predilection, HVLPDs (severe HVLL) are endemic among children young adults Asia Latin America.